NCT01098500View on ClinicalTrials.gov

Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

CompletedOBSERVATIONAL
Enrollment

3,800

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Cancer
Interventions
DRUG

Tyrosine kinase inhibitors

Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY